Progenics Pharmaceuticals Announces Fourth Quarter and Year-End 2012 Financial Results
Net loss for the fourth quarter was
Fourth quarter revenue totaled
Royalty income for the quarter was
Net sales reported to Progenics by Salix (in millions):
|Three Months Ended||Year Ended|
Fourth quarter and full year research and development expenses decreased by
Fourth Quarter Highlights
Completed underwritten public offering of 12,650,000 primary common shares resulting in
$23.3 millionnet proceeds.
Out-licensed C. difficile preclinical program for
$5.0 millionupfront payment (received in January) with potential future milestones and royalties.
- Fourth quarter Relistor global net sales increased 8% from the third quarter, but decreased 40% from the prior year period due to 2011 stocking activity. Annual Relistor global net sales increased 23% over 2011.
- Acquired Molecular Insight Pharmaceuticals, expanding our oncology pipeline with diagnostic and small molecule therapeutic candidates targeting PSMA and prostate cancer.
- Reported positive clinical data from a study of two novel radiolabeled small molecule imaging agents — 123I-MIP-1072 and 123I-MIP-1095 — targeting PSMA.
Conference Call and Webcast
Progenics will review fourth quarter and year-end financial results in a conference call today at
- Financial Tables follow -
|CONSOLIDATED STATEMENTS OF OPERATIONS|
|(in thousands, except net (loss) income per share)|
For the Three Months Ended
For the Year Ended
|Royalty income||$ 782||$ 1,279||$ 4,963||$ 3,046|
|Research and development||5,423||8,296||31,840||53,183|
|License fees — research and development||510||12||1,170||578|
|General and administrative||2,953||4,035||14,706||18,248|
|Depreciation and amortization||261||485||1,324||2,066|
|Operating (loss) income||(341)||(10,762)||(35,491)||10,316|
|Total other income||17||16||60||65|
|Net (loss) income before income taxes||(324)||(10,746)||(35,431)||10,381|
|Income tax benefit||--||--||--||--|
|Net (loss) income||$ (324)||$ (10,746)||$ (35,431)||$ 10,381|
|Net (loss) income per share; basic||$ (0.01)||$ (0.32)||$ (1.02)||$ 0.31|
|Weighted average shares outstanding; basic||37,590||33,700||34,754||33,375|
|Net income (loss) per share; diluted||$ (0.01)||$ (0.32)||$ (1.02)||$ 0.31|
|Weighted average shares outstanding; diluted||37,590||33,700||34,754||33,494|
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|Cash and cash equivalents||$ 58,838||$ 70,105|
|Auction rate securities||3,240||3,332|
|Fixed assets, net||3,399||4,038|
|Total assets||$ 76,308||$ 80,110|
|Liabilities||$ 8,902||$ 7,943|
|Total liabilities and stockholders' equity||$ 76,308||$ 80,110|
Progenics has exclusively licensed development and commercialization rights for its first commercial product, Relistor, to Salix Pharmaceuticals, Ltd. for markets worldwide other than
Important Safety Information for subcutaneous Relistor
Relistor is indicated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Use of Relistor beyond four months has not been studied.
Relistor is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction. If severe or persistent diarrhea occurs during treatment, advise patients to discontinue therapy with Relistor and consult their physician. Use of Relistor has not been studied in patients with peritoneal catheters.
Safety and efficacy of Relistor have not been established in pediatric patients.
Rare cases of gastrointestinal (GI) perforation have been reported in advanced illness patients with conditions that may be associated with localized or diffuse reduction of structural integrity in the wall of the GI tract (i.e., cancer, peptic ulcer, Ogilvie's syndrome). Perforations have involved varying regions of the GI tract (e.g., stomach, duodenum, colon).
Use Relistor with caution in patients with known or suspected lesions of the GI tract. Advise patients to discontinue therapy with Relistor and promptly notify their physician if they develop severe, persistent, and/or worsening abdominal symptoms.
The most common adverse reactions reported with Relistor compared with placebo in clinical trials were abdominal pain (28.5% vs. 9.8%), flatulence (13.3% vs. 5.7%), nausea (11.5% vs. 4.9%), dizziness (7.3% vs. 2.4%), diarrhea (5.5% vs. 2.4%), and hyperhidrosis (6.7% vs. 6.5%).
Relistor full Prescribing Information for the U.S. is available at www.relistor.com.
This press release may contain projections and other forward-looking statements regarding future events. Such statements are predictions only, and are subject to risks and uncertainties that could cause actual events or results to differ materially. These risks and uncertainties include, among others, the cost, timing and results of clinical trials and other development activities; the unpredictability of the duration and results of regulatory review of New Drug Applications and Investigational NDAs; market acceptance for approved products; generic and other competition; the possible impairment of, inability to obtain and costs of obtaining intellectual property rights; and possible safety or efficacy concerns, general business, financial and accounting matters, litigation and other risks. More information concerning Progenics and such risks and uncertainties is available on its
website, and in its press releases and reports it files with the
Additional information concerning Progenics and its business may be available in press releases or other public announcements and public filings made after this release.
For more information, please visit www.progenics.com.
For more information about Relistor, please visit www.relistor.com.
Amy MartiniCorporate Affairs (914) 789-2816 email@example.com Kathleen FredriksenCorporate Development (914) 789-2871 firstname.lastname@example.org
News Provided by Acquire Media